We are live on
!
Find out more
CG
Carlyle Group Portfolio holdings
AUM
$10B
1-Year Est. Return
10.61%
This Fund
S&P 500
This Quarter
Est. Return
+2.44%
1 Year Est. Return
-10.61%
3 Year Est. Return
-7.98%
5 Year Est. Return
-20.78%
10 Year Est. Return
-1.56%
AUM
$10.6B
AUM Growth
-$2.95B
(-22%)
Cap. Flow
-$3.28B
Cap. Flow
% of AUM
-30.86%
Top 10 Holdings %
Top 10 Hldgs %
99.93%
Holding
21
New
1
Increased
–
Reduced
2
Closed
1
Avg Time Held
7.7
quarters
Top 10 Avg Time Held
5.1
quarters
Top 20 Avg Time Held
7.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Heartflow Inc
HTFL
|
+$555K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
StandardAero Inc
SARO
|
+$2.03B |
| 2 |
Medline Inc
MDLN
|
+$1.25B |
| 3 |
NuCana
NCNA
|
+$480K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.9% |
| 2 | Industrials | 20.59% |
| 3 | Real Estate | 0.23% |
| 4 | Technology | 0.22% |
| 5 | Communication Services | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Medline Inc
MDLN
$31.4B
| $8.33B | 78.4% |
187,083,713
-28,219,323
| -13% | -$1.25B |
2025 Q4
1 quarter
|
|
|
2
StandardAero Inc
SARO
$6.59B
| $2.18B | 20.58% |
84,587,035
-68,086,856
| -45% | -$2.03B |
2024 Q4
5 quarters
|
|
3
Phathom Pharmaceuticals
PHAT
$577M
| $38.8M | 0.37% |
3,496,808
| – | – |
2023 Q1
12 quarters
|
|
4
Pony AI Inc
PONY
$2.5B
| $22.3M | 0.21% |
2,362,447
| – | – |
2024 Q4
5 quarters
|
|
5
Invitation Homes
INVH
$15.8B
| $16.5M | 0.16% |
664,100
| – | – |
2023 Q1
12 quarters
|
|
6
CubeSmart
CUBE
$8.54B
| $8.08M | 0.08% |
220,500
| – | – |
2022 Q3
14 quarters
|
|
7
Q32 Bio
QTTB
$260M
| $7.08M | 0.07% |
1,102,741
| – | – |
2024 Q1
8 quarters
|
|
8
DELISTED
GETTY IMAGES HLDGS INC A
GETY
| $4.95M | 0.05% |
6,234,252
| – | – |
2022 Q4
13 quarters
|
|
9
Spruce Biosciences
SPRB
$123M
| $2.52M | 0.02% |
38,620
| – | – |
2025 Q3
2 quarters
|
|
10
Forward Air
FWRD
$533M
| $1.79M | 0.02% |
107,214
| – | – |
2024 Q3
6 quarters
|
|
11
Adicet Bio
ACET
$51.8M
| $1.26M | 0.01% |
184,295
| – | – |
2023 Q1
12 quarters
|
|
12
Krispy Kreme
DNUT
$526M
| $1.16M | 0.01% |
340,748
| – | – |
2024 Q1
8 quarters
|
|
13
OnKure Therapeutics
OKUR
$98M
| $1.12M | 0.01% |
269,895
| – | – |
2023 Q1
12 quarters
|
|
14
Jasper Therapeutics
JSPR
$18.5M
| $934K | 0.01% |
1,066,189
| – | – |
2023 Q1
12 quarters
|
|
15
SunPower Inc
SPWR
$55.5M
| $550K | 0.01% |
433,158
| – | – |
2023 Q3
10 quarters
|
|
|
16
Heartflow Inc
HTFL
$4.4B
| $497K | ﹤0.01% |
+20,438
| New | +$555K |
2026 Q1
0 quarters
|
|
17
Spyre Therapeutics
SYRE
$8.03B
| $485K | ﹤0.01% |
9,620
| – | – |
2025 Q4
1 quarter
|
|
18
N-able
NABL
$852M
| $438K | ﹤0.01% |
93,732
| – | – |
2024 Q1
8 quarters
|
|
19
Exicure
XCUR
$7.14M
| $240K | ﹤0.01% |
56,328
| – | – |
2023 Q1
12 quarters
|
|
20
Robinhood
HOOD
$98.2B
| $234K | ﹤0.01% |
3,376
| – | – |
2025 Q4
1 quarter
|
|
|
21
NuCana
NCNA
$4.49M
| – | – |
-133,333
| Closed | -$480K | – |
|
Similar funds
LA
NW
AC
BCM
OIAM
AI
AI
SWP
Carlyle Group's Q1 2026 Portfolio in Review
As of Q1 2026, Carlyle Group held 21 positions worth $10.6B, down 22% from $13.6B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Carlyle Group withdrew a net $3.28B in Q1 2026, closing 1 position and reducing 2 holdings. Its most notable exit was NuCana, an estimated $480K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 67% a quarter earlier, followed by Industrials and Real Estate.
Against the trend, Carlyle Group opened a new position in Heartflow Inc worth $497K.
- Carlyle Group's largest Q1 2026 buy was Heartflow Inc: 20,438 shares worth $497K.
- Carlyle Group's biggest Q1 2026 reduction was StandardAero Inc, cutting an estimated $2.03B.
- Carlyle Group fully exited NuCana in Q1 2026, selling an estimated $480K.
- Carlyle Group's ten largest holdings make up 100% of its $10.6B portfolio in Q1 2026.
- Carlyle Group opened 1 new position and closed 1 in Q1 2026.
- Carlyle Group's portfolio value fell 22% quarter-over-quarter to $10.6B.
Based on Carlyle Group's 13F filing for Q1 2026, filed 8 May 2026.